Sorry, you need to enable JavaScript to visit this website.

CAVERJECT® IMPULSE (alprostadil) Overdosage


Overdosage was not observed in clinical trials with CAVERJECT IMPULSE. If intracavernous overdose of CAVERJECT IMPULSE occurs, the patient should be under medical supervision until any systemic effects have resolved and/or until penile detumescence has occurred. Treatment of any systemic symptoms (e.g., hypotension) would be appropriate.

What's New

No Current Announcements.

Contact Pfizer Medical


Please enter your search term(s) for CAVERJECT® IMPULSE